Abstract 625P
Background
Tumor markers have been used for cancer screening and monitoring, yet their potential connection with air pollution remains largely unexplored. We aimed to examine the potential association between various air pollutants – including carbon monoxide (CO), nitrogen dioxide (NO2), sulfur dioxide (SO2), PM2.5, and PM10 – and the levels of tumor markers (AFP, CEA, CA19-9, CA125, and PSA) within the general population.
Methods
Our study included 10,067 men and 9,598 women in its final analysis. We assessed each individual's annual average exposure to five distinct air pollutants: PM2.5, PM10, NO2, SO2, and CO. Additionally, we measured serum concentrations of AFP, CEA, CA19-9, CA125, and PSA.
Results
After adjusting for potential confounding factors, we discovered noteworthy associations. Both men and women demonstrated a negative correlation between annual average exposure to SO2 and PM10 and AFP concentration (all P < 0.05). In men, after multivariate adjustment, exposure to CO, NO2, SO2, and PM10 showed negative correlations with CEA concentration (all P < 0.05). Furthermore, in men, exposure to CO, NO2, and PM10 exhibited positive associations with PSA concentration after multivariate adjustment (all P < 0.05). Among women, a similar multivariate analysis indicated that SO2 exposure was negatively correlated with CEA concentration (all P < 0.05).
Conclusions
Our study presents the first evidence of a potential link between air pollution exposure and tumor markers within the general population. To establish the validity of these associations, further investigations employing prospective analyses are warranted.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The author.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
62P - Combination of chemotherapy with endocrinal therapy as upfront treatment of metastatic breast cancer in hormone receptor- positive, HER2 -negative disease: A phase II randomised clinical trial
Presenter: Mariam Saleh
Session: Poster Display
Resources:
Abstract
63P - Efficacy and safety of eribulin plus carboplatin combination for HER2-negative metastatic breast cancer
Presenter: Mengqian Ni
Session: Poster Display
Resources:
Abstract
64P - Unmet needs following metastatic breast cancer in a middle-income Asian country
Presenter: Nirmala Bhoo-Pathy
Session: Poster Display
Resources:
Abstract
66P - Utidelone-based therapy in metastatic solid tumors after failure of standard therapies: A prospective, multicenter, single-arm trial
Presenter: Jianjun Zhang
Session: Poster Display
Resources:
Abstract
67P - Efficacy and safety of trastuzumab biosimilar in HER2+ve metastatic breast cancer: A multicenter phase III study
Presenter: krishna Mohan
Session: Poster Display
Resources:
Abstract
68P - Neratinib in combination with fulvestrant and or palbociclib can overcome endocrine resistance in HER2-low/ ER+ breast cancer
Presenter: Maryam Arshad
Session: Poster Display
Resources:
Abstract
69P - A multicenter, retrospective, real-world study of inetetamab combined with pyrotinib and vinorelbine as treatment for HER2-positive metastatic breast cancer
Presenter: Nan Jin
Session: Poster Display
Resources:
Abstract
70P - Overall survival of eribulin, trastuzumab, and pertuzumab as first-line therapy for patients with HER2-positive metastatic breast cancer: A phase II, single-arm clinical trial
Presenter: Kenichi Inoue
Session: Poster Display
Resources:
Abstract
71P - Efficacy and safety of disitamab vedotin after trastuzumab for HER2 -positive breast cancer: A real-world data of retrospective study
Presenter: Chao Li
Session: Poster Display
Resources:
Abstract
72P - Real-world data on the efficacy of T-DM1 biosimilar for the treatment of HER2-positive metastatic breast cancer patients: Outcomes from a single center retrospective study in India
Presenter: Kaushal Patel
Session: Poster Display
Resources:
Abstract